Wednesday 18 Jun, 2025 04:03 PM
Site map | Locate Us | Login
   Reliance Infra jumps after landmark Dassault jet deal    Ratnabhumi Developers jumps 108% in fourteen days    Indusind Bank jumps on brokerage upgrade    Orient Cement Ltd leads losers in 'A' group    GTV Engg rises after securing Rs 2-cr export order from Metso India    KBC Global Ltd leads losers in 'B' group    Volumes spurt at Hindustan Zinc Ltd counter    Sakar Healthcare surges after receiving marketing authorization in EU for its oncology product    Steel Authority of India Ltd slips for fifth straight session    Hathway Cable & Datacom Ltd slips for fifth straight session    NLC India Ltd down for fifth straight session    Petronet LNG Ltd drops for fifth straight session    Exide Industries Ltd down for fifth straight session    Tata Motors Ltd slips for fifth straight session    Samvardhana Motherson International Ltd down for fifth straight session 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Glenmark pharma's US facility receives five observations after USFDA GMP inspection
18-Jun-25   09:51 Hrs IST

According to a regulatory filing by the company, the USFDA conducted a good manufacturing practices (GMP) inspection at the Monroe site from 9 June to 17 June 2025. Following the conclusion of the inspection, the USFDA has issued a Form 483 with five observations. Glenmark clarified that all the observations are procedural in nature and none pertain to data integrity.

The company stated that it will work closely with the USFDA to address the observations and will submit its response within the stipulated timeline.

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.

On a consolidated basis, Glenmark Pharmaceuticals reported net profit of Rs 4.65 crore in Q4 March 2025 as against net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025.

The counter shed 0.30% to Rs 1,648.80 on the BSE.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | Rights & Obligations-English | (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking | Policy GTC | Policy On Inactive Trading Accounts | Risk Disclosure Hit Count : 42032047
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited